AccuMetab™ Canine CYP2C21 Enzyme, Catalytically Active

CAT#: ITS-0426-YL35
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Canine CYP2C21 for reliable preclinical Phase I ADME profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
CYP2C21 is a key hepatic Phase I enzyme in dogs, sharing substrate overlap with human CYP2C and CYP3A families. Understanding its specific catalytic activity is essential to avoid toxicological surprises when scaling weak acid or neutral drug candidates from canine safety trials to human studies.
Key Features
Canine equivalent for weakly acidic drugs; Clarifies cross-species metabolic differences; Prevents toxicity surprises in preclinical trials; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Preclinical Species Comparison
Research Areas
ADME; Veterinary Pharmacology
Species
Beagle
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
1 nmol
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry